Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 3/20 | 0.37 |
| ▸ | FKBP1A | P62942 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10648552 | 0.92 | CYP1A2 (0.59) | CYP1A2SIGMAR1EPHX1NAAA | |
| SCHEMBL16387827 | 0.91 | CYP1A2 (0.71) | CYP1A2SIGMAR1SMN1; SMN2EPHX1HRH3 | |
| SCHEMBL23014720 | 0.89 | CYP1A2 (0.56) | CYP1A2SIGMAR1EPHX1NAAA | |
| SCHEMBL6937266 | 0.89 | CYP1A2 (0.54) | CYP1A2SIGMAR1SMN1; SMN2EPHX1NAAA | |
| SCHEMBL9267046 | 0.89 | CYP1A2 (0.56) | CYP1A2SIGMAR1SMN1; SMN2EPHX1HRH3 | |
| SCHEMBL29101110 | 0.89 | CYP1A2 (0.56) | CYP1A2SIGMAR1SMN1; SMN2EPHX1HRH3 | |
| SCHEMBL16404829 | 0.86 | CYP1A2 (0.50) | CYP1A2SIGMAR1SMN1; SMN2 | |
| SCHEMBL14739553 | 0.86 | CYP1A2 (0.52) | CYP1A2SIGMAR1SMN1; SMN2EPHX1HRH3 | |
| SCHEMBL22857774 | 0.85 | CYP1A2 (0.61) | CYP1A2SIGMAR1NAAA | |
| SCHEMBL23014885 | 0.85 | CYP1A2 (0.50) | CYP1A2SIGMAR1EPHX1HRH3NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312605-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2023-10-05 | — | — | US | disclosed |
| EP-1781640-B1 | 2,4-DI(AMINOPHENYL)PYRIMIDINE DERIVATIVES AS PLK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2015-01-07 | — | — | EP | disclosed |
| EP-1827441-B1 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION | BOEHRINGER INGELHEIM INT (DE) | 2011-06-15 | — | — | EP | disclosed |
| US-20050113536-A1 | Epoxy polymer precursors and epoxy polymers resistant to damage by high-energy radiation | ARMSTRONG SEAN E (US) | 2005-05-26 | — | — | US | disclosed |
| US-20050107580-A1 | Epoxy polymer precursors and epoxy polymers resistant to damage by high-energy radiation | ARMSTRONG SEAN E (US) | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312605-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK2, DYRK1B | CYP1A2 3647/4885SIGMAR1 2828/4885SMN1; SMN2 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.